Inhibition of effector B cells by ibrutinib in systemic sclerosis

Inhibition of effector B cells by ibrutinib in systemic sclerosis

Abstract Objective Systemic sclerosis (SSc) is a connective tissue disease with a significant morbidity and reduced survival of patients. Effective treatment and clinical control of the disease remain challenging. In particular, the development of pulmonary and cardiac fibrosis and pulmonary hyperte...

Full description

Bibliographic Details
Main Authors: Jakob Einhaus, Ann-Christin Pecher, Elisa Asteriti, Hannes Schmid, Kathy-Ann Secker, Silke Duerr-Stoerzer, Hildegard Keppeler, Reinhild Klein, Corina Schneidawind, Joerg Henes, Dominik Schneidawind
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Arthritis Research & Therapy
Subjects:
Systemic sclerosis
B cells
Ibrutinib
Autoimmune disease
Treatment
Online Access:http://link.springer.com/article/10.1186/s13075-020-02153-8

Internet

http://link.springer.com/article/10.1186/s13075-020-02153-8

Similar Items